---
input_text: "Blood transfusion for preventing primary and secondary stroke in people
  with sickle cell disease. BACKROUND: Sickle cell disease is one of the commonest
  severe monogenic disorders in the world, due to the inheritance of two abnormal
  haemoglobin (beta globin) genes. Sickle cell disease can cause severe pain, significant
  end-organ damage, pulmonary complications, and premature death. Stroke affects around
  10% of children with sickle cell anaemia (HbSS). Chronic blood transfusions may
  reduce the risk of vaso-occlusion and stroke by diluting the proportion of sickled
  cells in the circulation.This is an update of a Cochrane Review first published
  in 2002, and last updated in 2013. OBJECTIVES: To assess risks and benefits of chronic
  blood transfusion regimens in people with sickle cell disease for primary and secondary
  stroke prevention (excluding silent cerebral infarcts). SEARCH METHODS: We searched
  for relevant trials in the Cochrane Library, MEDLINE (from 1946), Embase (from 1974),
  the Transfusion Evidence Library (from 1980), and ongoing trial databases; all searches
  current to 04 April 2016.We searched the Cochrane Cystic Fibrosis and Genetic Disorders
  Group Haemoglobinopathies Trials Register: 25 April 2016. SELECTION CRITERIA: Randomised
  controlled trials comparing red blood cell transfusions as prophylaxis for stroke
  in people with sickle cell disease to alternative or standard treatment. There were
  no restrictions by outcomes examined, language or publication status. DATA COLLECTION
  AND ANALYSIS: Two authors independently assessed trial eligibility and the risk
  of bias and extracted data. MAIN RESULTS: We included five trials (660 participants)
  published between 1998 and 2016. Four of these trials were terminated early. The
  vast majority of participants had the haemoglobin (Hb)SS form of sickle cell disease.Three
  trials compared regular red cell transfusions to standard care in primary prevention
  of stroke: two in children with no previous long-term transfusions; and one in children
  and adolescents on long-term transfusion.Two trials compared the drug hydroxyurea
  (hydroxycarbamide) and phlebotomy to long-term transfusions and iron chelation therapy:
  one in primary prevention (children); and one in secondary prevention (children
  and adolescents).The quality of the evidence was very low to moderate across different
  outcomes according to GRADE methodology. This was due to the trials being at a high
  risk of bias due to lack of blinding, indirectness and imprecise outcome estimates.
  Red cell transfusions versus standard care Children with no previous long-term transfusionsLong-term
  transfusions probably reduce the incidence of clinical stroke in children with a
  higher risk of stroke (abnormal transcranial doppler velocities or previous history
  of silent cerebral infarct), risk ratio 0.12 (95% confidence interval 0.03 to 0.49)
  (two trials, 326 participants), moderate quality evidence.Long-term transfusions
  may: reduce the incidence of other sickle cell disease-related complications (acute
  chest syndrome, risk ratio 0.24 (95% confidence interval 0.12 to 0.48)) (two trials,
  326 participants); increase quality of life (difference estimate -0.54, 95% confidence
  interval -0.92 to -0.17) (one trial, 166 participants); but make little or no difference
  to IQ scores (least square mean: 1.7, standard error 95% confidence interval -1.1
  to 4.4) (one trial, 166 participants), low quality evidence.We are very uncertain
  whether long-term transfusions: reduce the risk of transient ischaemic attacks,
  Peto odds ratio 0.13 (95% confidence interval 0.01 to 2.11) (two trials, 323 participants);
  have any effect on all-cause mortality, no deaths reported (two trials, 326 participants);
  or increase the risk of alloimmunisation, risk ratio 3.16 (95% confidence interval
  0.18 to 57.17) (one trial, 121 participants), very low quality evidence. Children
  and adolescents with previous long-term transfusions (one trial, 79 participants)We
  are very uncertain whether continuing long-term transfusions reduces the incidence
  of: stroke, risk ratio 0.22 (95% confidence interval 0.01 to 4.35); or all-cause
  mortality, Peto odds ratio 8.00 (95% confidence interval 0.16 to 404.12), very low
  quality evidence.Several review outcomes were only reported in one trial arm (sickle
  cell disease-related complications, alloimmunisation, transient ischaemic attacks).The
  trial did not report neurological impairment, or quality of life. Hydroxyurea and
  phlebotomy versus red cell transfusions and chelationNeither trial reported on neurological
  impairment, alloimmunisation, or quality of life. Primary prevention, children (one
  trial, 121 participants)Switching to hydroxyurea and phlebotomy may have little
  or no effect on liver iron concentrations, mean difference -1.80 mg Fe/g dry-weight
  liver (95% confidence interval -5.16 to 1.56), low quality evidence.We are very
  uncertain whether switching to hydroxyurea and phlebotomy has any effect on: risk
  of stroke (no strokes); all-cause mortality (no deaths); transient ischaemic attacks,
  risk ratio 1.02 (95% confidence interval 0.21 to 4.84); or other sickle cell disease-related
  complications (acute chest syndrome, risk ratio 2.03 (95% confidence interval 0.39
  to 10.69)), very low quality evidence. Secondary prevention, children and adolescents
  (one trial, 133 participants)Switching to hydroxyurea and phlebotomy may: increase
  the risk of sickle cell disease-related serious adverse events, risk ratio 3.10
  (95% confidence interval 1.42 to 6.75); but have little or no effect on median liver
  iron concentrations (hydroxyurea, 17.3 mg Fe/g dry-weight liver (interquartile range
  10.0 to 30.6)); transfusion 17.3 mg Fe/g dry-weight liver (interquartile range 8.8
  to 30.7), low quality evidence.We are very uncertain whether switching to hydroxyurea
  and phlebotomy: increases the risk of stroke, risk ratio 14.78 (95% confidence interval
  0.86 to 253.66); or has any effect on all-cause mortality, Peto odds ratio 0.98
  (95% confidence interval 0.06 to 15.92); or transient ischaemic attacks, risk ratio
  0.66 (95% confidence interval 0.25 to 1.74), very low quality evidence. AUTHORS'
  CONCLUSIONS: There is no evidence for managing adults, or children who do not have
  HbSS sickle cell disease.In children who are at higher risk of stroke and have not
  had previous long-term transfusions, there is moderate quality evidence that long-term
  red cell transfusions reduce the risk of stroke, and low quality evidence they also
  reduce the risk of other sickle cell disease-related complications.In primary and
  secondary prevention of stroke there is low quality evidence that switching to hydroxyurea
  with phlebotomy has little or no effect on the liver iron concentration.In secondary
  prevention of stroke there is low-quality evidence that switching to hydroxyurea
  with phlebotomy increases the risk of sickle cell disease-related events.All other
  evidence in this review is of very low quality."
raw_completion_output: |-
  primary_disease: Sickle cell disease
  medical_actions: Blood transfusion; Chronic blood transfusions; Red cell transfusions; Hydroxyurea and phlebotomy; Long-term transfusions; Iron chelation therapy
  symptoms: Severe pain; End-organ damage; Pulmonary complications; Premature death; Stroke; Acute chest syndrome; Transient ischaemic attacks; Neurological impairment; Sickle cell disease-related serious adverse events
  chemicals: Hydroxyurea
  action_annotation_relationships: Blood transfusion (with hydroxyurea) PREVENTS stroke IN Sickle cell disease; Chronic blood transfusions TREATS Severe pain IN Sickle cell disease; Red cell transfusions PREVENTS Stroke IN Sickle cell disease; Long-term transfusions TREATS Acute chest syndrome IN Sickle cell disease; Iron chelation therapy TREATS End-organ damage IN Sickle cell disease; Hydroxyurea and phlebotomy PREVENTS Stroke IN Sickle cell disease; Hydroxyurea and phlebotomy INCREASES risk of sickle cell disease-related serious adverse events IN Sickle cell disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Hydroxyurea and phlebotomy INCREASES risk of sickle cell disease-related serious adverse events IN Sickle cell disease

  ===

extracted_object:
  primary_disease: MONDO:0011382
  medical_actions:
    - MAXO:0000756
    - Chronic blood transfusions
    - Red cell transfusions
    - Hydroxyurea and phlebotomy
    - Long-term transfusions
    - Iron chelation therapy
  symptoms:
    - Severe pain
    - End-organ damage
    - Pulmonary complications
    - Premature death
    - HP:0001297
    - Acute chest syndrome
    - HP:0002326
    - Neurological impairment
    - Sickle cell disease-related serious adverse events
  chemicals:
    - CHEBI:44423
  action_annotation_relationships:
    - subject: MAXO:0000756
      predicate: PREVENTS
      object: HP:0001297
      qualifier: MONDO:0011382
      subject_qualifier: with hydroxyurea
      subject_extension: CHEBI:44423
    - subject: <Chronic blood transfusions>
      predicate: <TREATS>
      object: <Severe pain>
      qualifier: <Sickle cell disease>
      subject_qualifier: <None>
      object_qualifier: <Severe>
      subject_extension: <None>
      object_extension: <None>
    - subject: Red cell transfusions
      predicate: PREVENTS
      object: HP:0001297
      qualifier: MONDO:0011382
    - subject: Long-term transfusions
      predicate: TREATS
      object: Acute chest syndrome
      qualifier: MONDO:0011382
    - subject: Iron chelation therapy
      predicate: TREATS
      object: End-organ damage
      qualifier: MONDO:0011382
      subject_extension: Iron chelation therapy
    - subject: phlebotomy
      predicate: PREVENTS
      object: HP:0001297
      qualifier: MONDO:0011382
      subject_extension: CHEBI:44423
    - subject: Hydroxyurea and phlebotomy
      predicate: INCREASES risk of
      object: sickle cell disease-related serious adverse events
      qualifier: MONDO:0011382
      subject_extension: Hydroxyurea, phlebotomy
named_entities:
  - id: MONDO:0007374
    label: Sickle Cell Disease (SCD)
  - id: MAXO:0001479
    label: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: HP:0001923
    label: Increased reticulocyte counts
  - id: CHEBI:80240
    label: Endothelin-1
  - id: MONDO:0011382
    label: Sickle Cell Disease
  - id: HP:0001945
    label: fever
  - id: HP:0002754
    label: osteomyelitis
  - id: CHEBI:17334
    label: penicillin
  - id: MAXO:0000118
    label: immunization
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MAXO:0001001
    label: Gene therapy
  - id: MAXO:0009101
    label: Early intervention
  - id: HP:0000989
    label: pruritus
  - id: HP:0012393
    label: allergic reactions
  - id: HP:0012532
    label: chronic pain
  - id: HP:0007760
    label: SCD
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:6807
    label: Methadone
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:82557
    label: Treosulfan
  - id: MAXO:0000756
    label: Blood transfusions
  - id: HP:0012531
    label: Pain
  - id: CHEBI:44423
    label: Hydroxyurea
  - id: MONDO:0005632
    label: Acute Chest Syndrome
  - id: CHEBI:35480
    label: analgesics
  - id: CHEBI:49005
    label: Deferasirox
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0030157
    label: Flank pain
  - id: HP:0100749
    label: Chest pain
  - id: HP:0001878
    label: Hemolytic anemia
  - id: MONDO:0005570
    label: Hematological diseases
  - id: HP:0004444
    label: Spherocytosis
  - id: HP:0001028
    label: Hemangioma
  - id: HP:0001871
    label: Hematological diseases
  - id: MONDO:0017014
    label: children
  - id: HP:0030830
    label: crackles
  - id: HP:0002617
    label: Vasculopathy
  - id: MONDO:0005380
    label: Avascular necrosis
  - id: HP:0002829
    label: Joint pain
  - id: MAXO:0000586
    label: Invasive ventilation (not used)
  - id: MONDO:0006502
    label: Severe COVID-19 with acute respiratory distress syndrome (ARDS)
  - id: HP:0002094
    label: dyspnea
  - id: HP:0001873
    label: thrombocytopenia
  - id: MONDO:0003664
    label: Haemolytic anaemia
  - id: HP:0025435
    label: increased lactate dehydrogenase levels
  - id: HP:0011981
    label: pigment gallstones
  - id: HP:0001907
    label: thromboembolism
  - id: CHEBI:35341
    label: steroids
  - id: HP:0001890
    label: autoimmune haemolytic anaemia
  - id: MAXO:0000457
    label: Pain management
  - id: MAXO:0010030
    label: Bone marrow transplantation (BMT)
  - id: HP:0001297
    label: Stroke
  - id: CHEBI:28901
    label: Busulfan
  - id: CHEBI:4031
    label: Cyclosporine
  - id: CHEBI:61049
    label: Tacrolimus
  - id: CHEBI:44185
    label: Methotrexate
  - id: HP:0001903
    label: Anemia
  - id: MONDO:0021200
    label: rare diseases
  - id: CHEBI:8093
    label: Phenylephrine
  - id: CHEBI:50858
    label: corticosteroids
  - id: HP:0002902
    label: Hyponatremia
  - id: CHEBI:26708
    label: Sodium
  - id: MAXO:0001175
    label: Liver transplantation
  - id: MAXO:0001394
    label: oral administration
  - id: MONDO:0004992
    label: Cancer
  - id: CHEBI:125354
    label: plerixafor
  - id: MAXO:0000149
    label: Hematopoietic cell transplantation (HCT)
  - id: MAXO:0000087
    label: Massage
  - id: MAXO:0000010
    label: Cognitive behavioral therapy
  - id: HP:0012432
    label: Chronic fatigue
  - id: HP:0000739
    label: Anxiety
  - id: HP:0000716
    label: Depression
  - id: MONDO:0044348
    label: Hemoglobinopathies
  - id: HP:0000083
    label: Renal failure
  - id: HP:0004395
    label: Malnutrition
  - id: HP:0100806
    label: Sepsis
  - id: HP:0002090
    label: Pneumonia
  - id: HP:0002878
    label: Respiratory failure
  - id: CHEBI:50443
    label: Autologous hematopoietic stem cell (HSC)-based gene therapy
  - id: MONDO:0005775
    label: Glucose-6-phosphate dehydrogenase deficiency
  - id: CHEBI:29016
    label: arginine
  - id: CHEBI:68554
    label: deferiprone
  - id: HP:0012649
    label: Increased inflammatory response
  - id: CHEBI:9570
    label: Thiotepa
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: HP:0002092
    label: Pulmonary hypertension
  - id: CHEBI:3216
    label: Buprenorphine
  - id: HP:0001139
    label: <Transcranial doppler (TCD) monitoring>
  - id: CHEBI:204928
    label: cefotaxime
  - id: HP:0001727
    label: Thromboembolic stroke
  - id: CHEBI:5588
    label: Hemoglobin A (HbA)
  - id: HP:0003095
    label: septic arthritis
  - id: HP:0002027
    label: abdominal pain
  - id: HP:0002013
    label: vomiting
  - id: HP:0001875
    label: neutropenia
  - id: HP:0012234
    label: agranulocytosis
  - id: CHEBI:4356
    label: deferoxamine
  - id: MONDO:0005354
    label: chronic hepatitis C
  - id: CHEBI:85083
    label: sofosbuvir
  - id: CHEBI:63580
    label: ribavirin
  - id: CHEBI:82977
    label: daclatasvir
  - id: CHEBI:85089
    label: ledipasvir
  - id: CHEBI:133009
    label: velpatasvir
  - id: CHEBI:132975
    label: grazoprevir
  - id: CHEBI:132967
    label: elbasvir
  - id: CHEBI:133008
    label: sofosbuvir/velpatasvir
  - id: CHEBI:17234
    label: glucose
  - id: HP:0200023
    label: Priapism
  - id: CHEBI:41879
    label: Dexamethasone
  - id: CHEBI:8764
    label: Mycophenolate mofetil
  - id: CHEBI:465284
    label: Ganciclovir
  - id: MONDO:0017291
    label: Reversible Cerebral Vasoconstriction Syndrome
  - id: CHEBI:9168
    label: Sirolimus
  - id: MONDO:0013730
    label: Graft-versus-host disease (GVHD)
  - id: CHEBI:2948
    label: azathioprine
  - id: CHEBI:33281
    label: antibiotics
  - id: MAXO:0000601
    label: dialysis
  - id: HP:0003774
    label: end-stage renal disease
  - id: CHEBI:17303
    label: Morphine
  - id: HP:0002326
    label: Transient ischaemic attacks
  - id: MAXO:0000068
    label: Transplantation
  - id: MAXO:0000427
    label: Brain magnetic resonance imaging
  - id: MAXO:0001259
    label: Angiography
  - id: HP:0011793
    label: Cerebral arteriopathy (CA)
  - id: MAXO:0000058
    label: drug treatment
  - id: CHEBI:10033
    label: warfarin
  - id: CHEBI:50249
    label: anticoagulants
  - id: HP:0004936
    label: venous thromboembolism (VTE)
  - id: HP:0004870
    label: Chronic hemolytic anemia
  - id: CHEBI:27690
    label: Acetazolamide
  - id: CHEBI:35143
    label: Hemoglobin
  - id: HP:0001971
    label: Hypersplenism
  - id: MONDO:0006260
    label: Renal medullary carcinoma (RMC)
  - id: MAXO:0000004
    label: surgery
  - id: MAXO:0000647
    label: chemotherapy
  - id: MAXO:0000014
    label: radiation
  - id: MONDO:0006079
    label: Acute Chest Syndrome (ACS)
  - id: MAXO:0001077
    label: Splenectomy
  - id: MAXO:0001484
    label: Gene editing therapy
  - id: MONDO:0008722
    label: Spontaneous Coronary Artery Dissection (SCAD)
  - id: HP:0040412
    label: Left ventricular thrombus
  - id: HP:0006702
    label: SCAD
  - id: MONDO:0002304
    label: Protein S deficiency
  - id: HP:0012418
    label: Hypoxemia
  - id: HP:0012419
    label: Hyperoxemia
  - id: CHEBI:25805
    label: Oxygen
  - id: MONDO:0011549
    label: Hyperhemolysis Syndrome (HHS)
  - id: HP:0001896
    label: Reticulocytopenia
  - id: CHEBI:64360
    label: Tocilizumab
  - id: MONDO:0019402
    label: Thalassemia Major
  - id: CHEBI:5855
    label: ibuprofen
  - id: MAXO:0000757
    label: infusion
  - id: HP:0002140
    label: Ischemic stroke
  - id: CHEBI:18050
    label: L-glutamine
  - id: HP:0002904
    label: Hyperbilirubinemia
  - id: HP:0001919
    label: Acute kidney injury
  - id: HP:0003256
    label: Coagulopathy
  - id: HP:0008209
    label: premature ovarian insufficiency (POI)
  - id: HP:0000488
    label: Retinopathy
  - id: HP:0001622
    label: Preterm birth
  - id: CHEBI:52717
    label: Bortezomib
  - id: CHEBI:27899
    label: cisplatin
  - id: CHEBI:28748
    label: doxorubicin
  - id: CHEBI:31355
    label: carboplatin
  - id: CHEBI:45863
    label: paclitaxel
  - id: CHEBI:175901
    label: gemcitabine
  - id: CHEBI:68478
    label: everolimus
  - id: MONDO:0019391
    label: Fanconi Anemia
  - id: HP:0045047
    label: High percentage of hemoglobin S (HbS%)
  - id: HP:0000822
    label: hypertension
  - id: HP:0012592
    label: albuminuria
  - id: HP:6000716
    label: hepatic sinusoidal obstruction syndrome
  - id: CHEBI:22720
    label: benzodiazepines
  - id: CHEBI:6539
    label: lorazepam
  - id: HP:0002039
    label: Anorexia
  - id: CHEBI:37153
    label: Calcineurin inhibitor
  - id: HP:0100602
    label: pre-eclampsia
  - id: MONDO:0000984
    label: thalassemia
  - id: MONDO:0018881
    label: myelodysplastic syndrome
  - id: MONDO:0010094
    label: Sickling crisis in sickle cell trait (SCT)
  - id: MAXO:0010032
    label: Cardiac transplantation
  - id: HP:0000790
    label: Hematuria
  - id: MAXO:0000194
    label: Opioid analgesics
  - id: HP:0003418
    label: Back pain
  - id: HP:0002653
    label: Bone pain
  - id: HP:0003326
    label: Muscle pain
  - id: CHEBI:35475
    label: Non-steroidal anti-inflammatory drugs (NSAIDs)
  - id: CHEBI:35482
    label: Opioid analgesics
  - id: MONDO:0005098
    label: Stroke
  - id: HP:0030149
    label: Cardiogenic shock
  - id: HP:0002014
    label: diarrhea
  - id: HP:0002018
    label: nausea
  - id: CHEBI:37708
    label: alanine aminotransferase (ALT)
  - id: CHEBI:28304
    label: Heparin
  - id: HP:0002315
    label: Headaches
  - id: HP:0011868
    label: Sciatica
  - id: HP:0100588
    label: Paraphimosis
  - id: HP:0000473
    label: Torticollis
  - id: HP:0100607
    label: Dysmenorrhea
  - id: HP:0410017
    label: Otitis externa
  - id: HP:6000040
    label: Neuropathic pain
  - id: CHEBI:64356
    label: Pregabalin
  - id: CHEBI:119915
    label: fentanyl
  - id: HP:0008527
    label: Congenital sensorineural hearing loss
  - id: HP:0002251
    label: Hirschsprung's disease
  - id: HP:0012450
    label: Chronic constipation
  - id: MONDO:0019518
    label: Waardenburg-Shah syndrome
  - id: CHEBI:5790
    label: Hydromorphone
  - id: CHEBI:67079
    label: Anti-inflammatory agents
  - id: MONDO:0007885
    label: osteonecrosis of the femoral head (ONFH)
  - id: HP:0005743
    label: osteonecrosis of the femoral head
  - id: HP:0030692
    label: brain tumor
  - id: MONDO:0021211
    label: brain tumor
  - id: MAXO:0000750
    label: Conditioning regimen
  - id: MAXO:0000159
    label: Treatment with analgesics
  - id: HP:0001511
    label: Fetal growth restriction
  - id: CHEBI:24996
    label: lactate
  - id: CHEBI:26806
    label: succinate
  - id: CHEBI:33709
    label: amino acids
  - id: CHEBI:17368
    label: hypoxanthine
  - id: CHEBI:15318
    label: xanthine
  - id: CHEBI:17775
    label: urate
  - id: HP:0031688
    label: dyserythropoiesis
  - id: MAXO:0000011
    label: physical therapy
  - id: HP:0030838
    label: hip pain
  - id: MAXO:0000602
    label: Hemodialysis
  - id: HP:0033578
    label: pre-capillary pulmonary hypertension
  - id: HP:0005317
    label: increased pulmonary vascular resistance (PVR)
  - id: HP:0012534
    label: Hyperalgesia
  - id: HP:0009830
    label: Neuropathy
  - id: MONDO:0006515
    label: Acute Pancreatitis
  - id: HP:0002155
    label: hypertriglyceridemia
  - id: HP:0001953
    label: diabetic ketoacidosis
  - id: HP:0001882
    label: leukopenia
  - id: HP:0003077
    label: hyperlipidemia
  - id: HP:0001735
    label: acute pancreatitis
  - id: HP:0001510
    label: Growth failure
  - id: HP:0000823
    label: Delayed puberty
  - id: HP:0000798
    label: Low sperm counts
  - id: MONDO:0005148
    label: Type 2 diabetes
  - id: MONDO:0005920
    label: Plasmodium falciparum Malaria
  - id: MONDO:0020617
    label: osteonecrosis of the knee (OK) secondary to sickle cell disease (SCD)
  - id: MAXO:0000451
    label: implantation
  - id: CHEBI:81579
    label: erythropoietin
  - id: MONDO:0004745
    label: Priapism
  - id: CHEBI:33568
    label: Adrenaline
  - id: CHEBI:6121
    label: Ketamine
  - id: HP:0033415
    label: pericardial tamponade
  - id: HP:0001250
    label: seizures
  - id: HP:0012622
    label: chronic kidney disease (CKD)
  - id: CHEBI:28876
    label: Melphalan
  - id: MONDO:0019740
    label: Thrombotic Thrombocytopenic Purpura (TTP)
  - id: HP:0001287
    label: Meningitis
  - id: CHEBI:2955
    label: Azithromycin
  - id: HP:0006554
    label: Acute Liver Failure
  - id: CHEBI:38157
    label: Iron chelators
  - id: HP:0001081
    label: cholelithiasis
  - id: CHEBI:6970
    label: mometasone
  - id: CHEBI:138154
    label: CXCL9
  - id: MAXO:0000945
    label: Spinal Cord Stimulation
  - id: HP:0031273
    label: Shock
  - id: CHEBI:63918
    label: Artesunate
  - id: CHEBI:32594
    label: barium
  - id: CHEBI:18248
    label: iron
  - id: MONDO:0100163
    label: Multisystem Inflammatory Syndrome in Children (MIS-C)
  - id: MAXO:0010033
    label: umbilical cord blood transplantation
  - id: HP:0011134
    label: Low-grade fever
  - id: HP:0001974
    label: Leukocytosis
  - id: CHEBI:28001
    label: Vancomycin
  - id: CHEBI:17833
    label: Gentamycin
  - id: CHEBI:35523
    label: Bronchodilators
  - id: CHEBI:16962
    label: Cortisone
  - id: CHEBI:23888
    label: drugs
  - id: MAXO:0000506
    label: Noninvasive ventilation (NIV)
  - id: MAXO:0000955
    label: Bilevel pressure (BiPAP)
  - id: HP:0032169
    label: Severe infection
  - id: HP:0100601
    label: Eclampsia
  - id: MONDO:0002492
    label: Acute kidney injury (AKI) and major adverse kidney events (MAKE)
  - id: MAXO:0000110
    label: Vitamin D supplementation
  - id: CHEBI:27300
    label: Vitamin D
  - id: HP:0003074
    label: hyperglycemia
  - id: CHEBI:27834
    label: Pentostatin
  - id: MONDO:0004981
    label: Atrial Fibrillation
  - id: HP:0005110
    label: Atrial Fibrillation
  - id: HP:0100543
    label: Cognitive deficits
  - id: HP:0000988
    label: skin eruptions
  - id: MONDO:0001705
    label: Pure red cell aplasia (PRCA)
  - id: HP:0012410
    label: Pure red cell aplasia (PRCA)
  - id: MONDO:0015194
    label: Sideroblastic anaemia
  - id: HP:0005505
    label: Refractory anaemia
  - id: HP:0010972
    label: ineffective erythropoiesis
  - id: HP:0002756
    label: spontaneous fractures
  - id: MAXO:0000588
    label: nucleic acid testing
  - id: HP:0030833
    label: neck pain
  - id: HP:0000613
    label: photophobia
  - id: HP:0025143
    label: chills
  - id: HP:0012378
    label: fatigue
  - id: HP:0004396
    label: loss of appetite
  - id: CHEBI:36751
    label: PCA
  - id: HP:0000112
    label: renal diseases
  - id: HP:0001392
    label: hepatic diseases
  - id: MAXO:0035088
    label: Clinical assessment of MRI/magnetic resonance angiography (MRA)
  - id: MAXO:0000487
    label: Clinical assessment
